Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
relmada therapeutics報告稱，數據監測委員會（DMC）評估表明，第三期Reliance II試驗在中期分析中是徒勞的，不太可能達到主要療效終點具有統計學意義。